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ASTHMA is  characterized  by  airway  inflammation,
which can be now assessed by the analysis of induced
sputum. Ten patients with asthma were investigated
during  acute  exacerbation  for  the  quantification  of
apoptosis,  for Bcl-2 and  Fas expression, in induced
sputum  lymphocytes.  They  were  compared  to  12
patients with chronic obstructive pulmonary disease
(COPD), and 10 healthy controls. Spontaneous apop-
tosis was determined by staining nuclei with propi-
dium iodide, and analyzed with a FACScan. Bcl-2 was
measured  by  Western  blotting,  and  results  were
obtained by densitometric scanning, done by the gel
proanalyser. The investigation of Fas was performed
using  the  streptavidin-biotin  preroxidase-complex
method.  Patients  with  asthma  and  patients  with
COPD exhibited a significant increase of cellularity,
percentage of neutrophils, eosinophils and lympho-
cytes when compared to healthy controls. Apoptosis
in  induced  sputum  mononuclear  cells  was  found
decreased in patients with asthma compared to COPD
patients and healthy controls. The quantification of
apoptosis  was  measured  after  exposure  to  anti-
cytokine antibodies. Anti-TNF-a antibody blocked the
apoptosis in both patients groups and healthy con-
trols,  suggesting  that  TNF-a acted  as  an  inducer  of
apoptosis.  Anti-IL-10  blocked  apoptosis  completely
exclusively in patients with asthma. Bcl-2 expression
was found to be increased in induced sputum mono-
nuclear cells from patients with asthma, compared to
healthy controls and patients with COPD. Expression
of Fas could be detected in patients with asthma, at a
lower level than COPD patients and healthy controls.
Distinct  mechanisms  of  apoptosis  were  found  in
patients with asthma and patients with COPD, charac-
terized by different levels of Bcl-2 and Fas expression.
Induction of apoptosis should be a beneficial process
in allergic inflammation traduced in induced sputum
mononuclear cells. The apoptosis process is assumed
by two different mechanisms in asthma and COPD.
Our  findings  indicated  that  in  asthmatic  patients,
activated  lymphocytes  accumulate  in  the  bronchi;
because  of  their  prolonged  survival  that  maintains
inflammation.
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Introduction
Infiltration  of  the  airways  mucosa  with  activated
inflammatory cells appears to be a major factor in the
pathogenesis of asthma  and  other forms of chronic
obstructive airway disorders, such as chronic obstruc-
tive pulmonary disease (COPD). The cells and molec-
ular markers of this inflammation have been studied
by bronchoalveolar lavage (BAL) and bronchial biop-
sies but the use of these techniques has been limited
in certain patients by their invasiveness. In order to
overcome the difficulties associated with bronchoal-
veolar lavage and the sampling of bronchial biopsies
via the bronchoscope, analysis of induced sputum has
recently  been  suggested  for  repeated  evaluation  of
airway inflammation in patients with asthma. Exam-
ination  of  induced  sputum  allows  investigation  the
airway inflammation directly without important sec-
ondary effects. Inflammatory markers can be studied
on cells and supernatants.
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Mediators of Inflammation, 8, 237–243 (1999)Inflammation plays a key role in the pathophysiol-
ogy of asthma1 and COPD. In bronchial biopsies of
patients  with  asthma,  primarily  eosinophils,  mono-
cytes/macrophages and T-lymphocytes1,2 are seen. In
lobar  bronchial  biopsies  of  subjects  with  chronic
bronchitis, an increased number of leukocytes, both in
the epithelium and in the lamina propria, consisting
predominantly of macrophages and activated T-cells,
was found. Eosinophils are the more prominent cells in
asthma, and their activation is supposed to be involved
in tissue destruction. Epithelial bronchial cells are now
considered essential  in modulating bronchial tissues
remodeling  (subepithelial  fibrosis,  muscular  hyper-
plasia). However, T-lymphocytes are still essential  in
asthma inflammation as the TH2 cytokines are charac-
teristic of allergic pathways and particularly of asthma.
Moreover, the major drugs used in asthma (steroids)
are  powerful  immunosuppressors,  reflecting  impor-
tance of the immunologic pathways.
Homeostasis of cell number is achieved by balanc-
ing  the  proliferative  and  anti-proliferative  states  of
cells. Anti-proliferative  states  include  growth  arrest,
differentiation,  senescence  (cellular  ageing),  and
apoptosis. Apoptosis, a dynamic process involved in
the  control  of  the ‘tissue  load’  of  immune  effector
cells  at  inflamed  sites,  tends  to  limit  inflammatory
tissue injury and  to promote resolution  rather than
progression of inflammation.3The inflammatory proc-
ess  could  be  traduced  by  certain  proto-oncogenes,
which regulate the programmed cell death: apoptosis.
Fas and  the members of the Bcl-2 gene family have
emerged as key regulators of the apoptotic process.4
In  bronchial  biopsies,  the  number  of  apoptotic
eosinophils and macrophages was found to be lower
in subjects with asthma than those with COPD and
inversely  correlated  with  the  clinical  severity  of
asthma,5 reflecting longer survival of these cells.
As lymphocytes are involved in the initial events of
recruitment and activation of inflammatory cells, we
supposed  that  they  have  to  disappear  to  allow
inflammation resolution. The aim of our study was to
investigate bronchial lymphocytes apoptosis in acute
asthma  exacerbation.  The  cells  were  recovered  on
induced sputum. In this work, we will discuss how
the  use  of  sputum,  and  the  analyses  of  apoptosis,
promise to provide new insights into understanding
inflammatory airway diseases.
Materials and methods
Patients
Induced  sputum  samples  were  collected  from  10
successive patients with asthma, and 12 patients with
COPD (Table 1). All were inpatients, admitted for an
acute wheezing exacerbation of dyspnea, usually by
the emergency services. The sample was obtained the
day  after  their  admission. A  precise  history  of  the
patient was subsequently obtained, and after recovery
functional respiratory tests and eventually skin tests
were realized. The following patients were excluded:
concomitant  infectious  pneumonia,  tuberculosis,
A. Hamzaoui et al.
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Table 1. Clinical manifestations and treatment. A: asthma; B: COPD; PY: pack year; GS: glucosteroids; y: yes; n: negative results;
asthma severity: 2: mild, 3: moderate, 4: severe.
Patients Age Smoking
PY
Atopy Reversi-
bility
Beta 2
test
GS
test
Skin
tests
Dyspnea history
(years)
Acute
dyspnea
Persistant
dyspnea
Asthma
severity
Productive
cough
Previous treatment
B2
agonists
Theo-
phylline
GS
Previous
hospitalis-
ations
(number)
A1 47 30 y p p 8 0 3 y y y y 2
A2 22 1 y p p 3 0 2 n n n y 1
A3 65 40 n p n 8 3 4 n y y y 4
A4 47 0 y p p 11 7 4 n n n n 1
A5 47 0 y p 5 0 2 n y y n 1
A6 80 0 n n n n 10 0,1 3 y n y y 2
A7 31 0 y n p p 26 1 4 n y y n 2
A8 30 15 y p p 12 0 2 n y y n 2
A9 28 0 y n p p 6 0 3 y y y y 3
A10 46 10 y p p 29 3 4 y n y y 2
B1 88 49 n n n p 20 9 n y y n 1
B2 71 124 n n n n 0,2 0,2 y n n n 1
B3 59 20 n n n 20 5 y y y y 3
B4 68 100 n n n 0 8 y n n n 1
B5 59 75 n n n p 10 1 y y y n 3
B6 65 20 n n n p 10 2 y y y y 1
B7 61 30 y n n 13 13 y n y n 1
B8 52 60 n n n n 15 3 n n n y 1
B9 82 20 n n n n 3 0 n n n n 1
B10 64 100 n n n n 40 1 y y y n 3
B11 63 69 n p p n 15 0,1 y n n n 1
B12 80 80 n p n 1 0 y n n n 1interstial  lung diseases,  bronchiectasis, lung cancer,
and associated acute pathologies: cardiac, renal, liver,
or neurological diseases.
Ten induced sputum from healthy subjects (mean
age 28.7 yrs; range 22–36), who had normal pulmo-
nary  radiographs  and  showed  no  clinical  signs  of
respiratory  diseases,  acted  as  controls.  Informed
consent was obtained from all the patients. The study
was approved by the local Ethics Committee.
Sputum induction
After  the  inhalation  of  salbutamol  (2  3 200 m g),
subjects  were  asked  to  inhale  sterile,  pyrogen-free,
hypertonic saline in  increasing concentrations for a
duration of 10min. The hypertonic saline was nebu-
lized  via  an  ultrasonic  nebulizer.  Subjects  were
encouraged to cough throughout the procedure. Most
patients were able to expectorate an adequate sample
(7 ml and more) within the first 10min.
Sputum processing
In  order  to  reduce  salivary  contamination,  plugs
were  selected  and  transferred  into  an  Eppendorf
tube. Freshly prepared 10% solution of dithiothreitol
(1 ml) (DTT) was added. The tube was vortex mixed
and  the  sputum  was  incubated  for  5 min  at  room
temperature, filtered through 52 m m nylon gauze to
remove  debris  and  mucus,  and  subsequently  cen-
trifuged  at  450 3 g  for  10min. The  cell  pellet  was
resuspended in phosphate-buffered saline (PBS) in a
volume  equal  to  the  sputum  plus  DTT  solution
volume.  Total  cell  counting  was  carried  out  in  a
haemocytometer  and  the  cell  concentration  was
adjusted  to  1.0  3 106 cells/ml.  Cytospins  were
prepared by adding 75 m l cell suspension into Shan-
don  II  cytocentrifuge  cups  (Shandon  Southern
Instruments)  and  spun  for  8 min  at  500rpm. Two
slides were stained with Wright-Giemsa for an over-
all  differential  cell  count  of  leukocytes,  bronchial
epithelial  cells  and  squamous  cells.  Slides  were
coded and counted blind by two investigators. None
of the cytospins contained >5% squamous epithelial
cells. For cell differentiation, 400 nucleated cells per
slide  were  counted (Table  2) and  expressed  as  the
percentage  of  intact  round  nucleated  cells,  exclud-
ing the squamous  epithelial  cells.
Quantification of apoptosis
Lymphocytes  were  isolated  by  Ficoll–Hypaque
(Pharmacia, Uppsala, Sweden) density gradient cen-
trifugation  and washed twice with  PBS  at  4+°C, as
we  have  recently  reported.5 Cell  pellet  expressed
more than 80% CD3-positive cells as determined by
anti-CD3  monoclonal  antibody  (Becton  Dickinson).
These T-cells were double labeled with anti-CD3 and
anti-CD25 monoclonal antibodies in original (Becton
Dickinson).
Apoptosis  was  quantified  on  lymphocytes  by
staining  nuclei  with  propidium  iodide  (PI)  and
analysing  fluorescence  with  a  FACScan  (Becton
Dickinson.  Mountain  View,  CA).  Briefly  following
culture  for  18h,  lymphocytes  were  collected  after
centrifugation with RPMI 1640 at  150g for 10min.
The pellet was washed twice in  complete medium
(RPMI  1640  supplemented  with  2mM  L-glutamine,
100U/ml  benzyl-penicillin,  100 m g/ml  streptomycin
and  containing  10%  fetal  calf  serum).  The  pellet
collected  from  induced  sputum  was  gently  sus-
pended in 0.5ml of hypotonic fluochrome solution
(0.1%  sodium  citrate  with  0.1% Triton  X-100) con-
taining  20mg  per  m l  PI  for  2Omin.  RNAse A  at  a
concentration of l0 mg/ml was added and cells were
further incubated for 10min at 4°C. The suspension
was  analyzed  by  flow  cytometry  to  determine  PI
fluorescence  of  individual  nuclei. Apoptotic  nuclei
appeared as a broad hypodiplo¨ õd DNA peak that was
easily discriminated from the narrow peak of nuclei
with normal (diploid) DNA content. Student’s t-test
was used for statistical analysis of data  and  p<0.01
was  taken  as significant.
Detection of Fas by immunochemistry
For  measuring  the  expression  of  the  Fas-antigen,
induced sputum cytospins were fixed with  ice-cold
acetone  for  10min.  Immunocytochemical  investiga-
tion of Fas was performed using the streptavidin-biotin
preroxidase-complex method. Cell preparations were
pre-incubated with hydrogen peroxide (0.3%, 15min),
unlabeled streptavidin (dilution 1:50, 15min) and non-
immune normal sheep serum. After each step slides
were  washed  three  times  in  PBS. The  Fas-antibody
antibody (Immunotech, France) was used in a dilution
Apoptosis in patients with asthma
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Table 2. Subjects’ cell characteristics.
Cells Asthma BPCO Healthy
controls
Number of 2.5 1.9 1.4
cells 3 10
6 (1,3–2,7) (0,9–2,1) (0.8–1.8)
Viability % 84 86 83.6
(45.5–94.5) (56.5–92.7) (75.6–92.0)
% macrophages 52.56 49.63 42.8
(40.3–62.9) (40.4–59.3) (22.7–65.0)
% neutrophils 32.85 35.49 28.0
(25.2–50.5) (24.8–46.5) (19.8–41.4)
% eosinophils 5.7 4.79 1.7
(2.7–9.5) (1.6–8.1) (0.6–2.9)
% lymphocytes 7.45 8.73 3.9
(4.2–12) (3.0–14.5) (0.5–4.3)
% epithelial cells 1.1 0.9 1.6
(0.2–5.6) (0.4–2.3) (1,4–6,7)as indicated  by the  manufacturer and  applied  over-
night at 4°C. After three washes in PBS the cells were
incubated  for  45min  with  biotinylated  sheep  anti-
mouse IgG (Amersham; diluted 1:50 with 5% normal
serum).  After  washing  three  times  with  PBS,  the
streptavidin-biotinylated peroxidase complex (Amer-
sham,  1:100,  30min)  was  added  and  subsequently
washed with PBS (three times). Peroxidase activity was
made visible with 3-amino 9-ethycarbazole (20min),
which gives a red-brown reacting product. Counter-
staining was performed with haematoxylin and sec-
tions were mounted with glycerol gelatine. Negative
controls were obtained, firstly, omitting the primary
antibodies and secondly, by an irrelevant antibody. For
Fas-antigen,  the  percentage  of  stained  cells  was
estimated  for  each  slide  and  the  samples  were
classified as cells with low Fas expression if less than
1.5% (mean value) stained cells were present and as
high Fas-expression samples if 1.5% or more of the cells
were stained.
Expression of Bcl-2 by western blotting
The expression of Bcl-2 in induced sputum lympho-
cytes  was  determined  by  Western  blotting.  Equal
amounts  of  protein  were  loaded  on  SDS-PAGE  and
blotted onto nitrocellulose paper. The Bcl-2 protein
was  detected  by  rabbit  anti-human  Bcl-2  antibody
(Santa Cruz Biotechnology, CA) and anti-rabbit perox-
idase conjugate as secondary antibody with diamino-
benzidine as substrate. Densitometric scanning of the
blot  was  done  by  the  gel  proanalyser  from  Media
Cybernetics.
Statistical analysis
Values  are  presented  as  mean  value  (SEM).  Differ-
ences between groups are analyzed using the Mann–
Whitney  U-test.  Probability  values  of  p<0.05  were
considered significant. Reproducibility of sputum cell
counts  was  examined  by  repeated-measures. Values
>0.70 indicate high reliability.
Results
Patients
According to clinical history, functional (spirometry,
and reversibility with beta2 agonists or steroids) and
skin tests results, patients were classified as asthmatic
patients  or  COPD.  Chronic  asthma  severity  was
classified according to GINA recommendations.6Three
patients were difficult to diagnose definitely as asthma
or COPD (A1, B11 and B12) but we decided not to
exclude them, the results obtained on their samples
reflecting a real association of the 2 diagnosis.
Differential cell counts
Differential cell count in induced sputum was repor-
ted in Table 2. Patients with COPD and patients with
asthma  exhibited  a  higher  total  cell  number,  an
increased  percentage  of  macrophages,  eosinophils
and  neutrophils when  compared to healthy control
induced sputum (p<0.01). Patients with asthma and
patients  with  COPD  exhibited  significant  increased
levels  of  lymphocytes  when  compared  to  healthy
controls (p<0.01).
Quantification of apoptosis
Induced  sputum  lymphocytes  from  patients  with
asthma,  patients  with  COPD  and  healthy  controls,
showed spontaneous apoptosis (mean ± s.e.m.) after
18h  of  culture  of  lymphocytes  in  the  absence  of
mitogens (Figure  1). These  lymphocytes  were  CD3-
and CD25-positive. The percentage of apoptosis was
significantly  decreased  in  patients  with  asthma
(11.37%  ±  5.31  %;  p<0.01)  compared  with  COPD
patients  (14.82%  ±  4.46% ),  and  healthy  controls
(26.09% ± 12.34% ).
Pathogenic concepts of allergic diseases include a
central  role  for  differential  cytokine  production,
characterized as Th0/Th2 profile. Then  we tested if
certain  anti-cytokines  antibodies  could  block  the
apoptosis in patients with asthma, with COPD and in
healthy controls.
A. Hamzaoui et al.
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FIG. 1. Percentage of apoptosis in patients with asthma (n = 10), in patients with COPD (n = 12), and in healthy controls (HC)
(n = 10).Induced sputum lymphocytes were cultured in the
presence of various anti-cytokine antibodies, anti-IL-2,
anti-IL-4, anti-IL-10, anti-IL-13, and anti-TNF-a (Fig. 1).
Anti-IL-2  antibodies  inhibited  the  apoptosis  both  in
patients with asthma and patients with COPD by 45%
and  7%  respectively.  Anti-IL-10  blocked  apoptosis
exclusively in patients with asthma by 70%. Anti-TNF-
a antibody inhibited the apoptosis in  both patients
groups  and  healthy  controls,  suggesting  that TNF-a
acted as an inducer of apoptosis.
Expression of Bcl-2 in induced sputum
mononuclear cells
The analysis of Bcl-2, which is the apoptosis inhibiting
protein,  was  estimated  by  Western  blotting.  The
results were highly reproducible. The concordance of
the repeated experiments was for Bcl-2 measurement
of 87%.
The expression of Bcl-2 was found to be increased
in  induced  sputum  lymphocytes  for  patients  with
asthma (32.7% ± 7.4%) compared to healthy controls
(16.8%   ±  6.2%)  and  patients  with  COPD  (13.9%   ±
2.8%)  (p<0.01)  (Fig.  2).  The  Bcl-2  level  was  not
significantly  different  in  patients  with  COPD,  and
healthy controls. The Bcl-2 levels were also detected
by two-color flow cytometry analysis (anti-CD3 and
anti-Bcl-2 monoclonal antibodies) and similar  results
were obtained. Cells with light scatter characteristics
of lymphocytes were gated and analyzed using LYSYS
II  software  from  FACScan  flow  cytometer  (Becton
Dickinson) (data not shown).7
Expression of fas in induced sputum
mononuclear cells
We  analyzed  10  samples  of  induced  sputum  from
patients  with  asthma,  from  patients  with  COPD
(n=12)  and  from  healthy  controls  (n=10)  for  Fas
expression.  The  percentage  of  stained  cells  was
estimated for each slide. The results were represented
individually for  each patient  (Fig. 3). A  significantly
Apoptosis in patients with asthma
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FIG. 2. Expression of Bcl-2 in induced sputum mononuclear cells from 10 patients with asthma, 12 patients with COPD, and 10
healthy controls (HC). Densitometric scanning of the Western blot quantifies the expression of Bcl-2.
FIG. 3. Expression of Fas in induced sputum mononuclear cells from 10 patients with asthma, 12 patients with COPD, and 10
healthy controls (HC). Individual values were expressed in percentage (number of Fas-positive cells/number of mononuclear
cells 3 100). Asthmatic patients number 4 and 10 [® ], have subnormal values of Fas-positive cells. According to Table 2, they
have low values of eosinophils.low expression of Fas could be detected in patients
with asthma, when compared to COPD patients and
to healthy controls (p<0.01).
Discussion
Total cell count was elevated in patients with asthma
and  patients with  COPD, compared to healthy  con-
trols.  Sputum  of  patients  with  asthma  and  COPD
expressed high percentages of eosinophils and lym-
phocytes. The lymphocytes were in the majority CD3-
positive  (T-lymphocytes),  and  were  activated
(CD25+). The leukocytes count and phenotype of the
lymphocytes showed that sputum traduced an inflam-
matory state in patients with asthma and COPD. The
results  obtained  from  analyzing  induced  sputum  in
asthma and COPD patients reflect the inflammatory
status of the bronchi.
The  percentage  of  apoptosis  was  significantly
decreased  in  patients  with  asthma  compared  with
COPD  patients  and  healthy  controls. Anti-IL-2  anti-
bodies inhibited the apoptosis both in patients with
asthma  and  patients with  COPD. Anti-IL-10 blocked
apoptosis  exclusively  in  patients  with  asthma. Anti-
TNF-a antibody  inhibited  the  apoptosis  in  both
patients groups and healthy controls, suggesting that
TNF-a acted as an inducer of apoptosis.
The expression of Bcl-2 was found to be increased
in  induced sputum lymphocytes from patients with
asthma  compared  to  healthy  controls  and  patients
with COPD.
A  significantly  low  expression  of  Fas  could  be
detected in patients with asthma, when compared to
COPD patients and to healthy controls.
No correlation was found with asthma severity, or
previous treatment. This can be linked to our proto-
col: all the samples were collected during an  acute
exacerbation requiring an admission. We can suppose
that  the  severity  of  the  acute  process  was  similar
within  the  patients  and  did  not  depend  on  the
severity of the chronic disease. It would only depend
on the pathology: asthma or COPD.
In an attempt to clarify if lymphocytes survival is
modified in asthma, we investigated induced sputum
samples.  The  percentage  of  apoptosis  was  signifi-
cantly decreased in  patients with asthma  compared
with  COPD  patients  and  healthy  controls.  The
decreased  apoptosis  observed  in  patients  may  be
associated with persistence of mononuclear cells in
the  bronchial  mucosa  and  lumen,  during  the  acute
exacerbations. The  low  expression  of  apoptosis  is
more  important  in  patients  with  asthma,  when
compared to COPD patients. This finding suggests a
particular  involvement  of  lymphocytes  in  acute
asthma. Induction of apoptosis allowing the removal
of  the  cells  may  be  essential  to  resolve  allergic
inflammation,  and  the  use  of  corticosteroids  and
theopylline  in  combination  may  be  appropriate  to
induce apoptosis in eosinophils and lymphocytes.8
Interestingly,  Vignola  et  al.5 found  significantly
more  apoptotic  cells  in  the  biopsy  specimens  of
patients with chronic bronchitis than in tissues from
asthmatic  patients. The  authors  reported  also5 that
there is an imbalance between the expression of Bcl-2
and  p53,  which  appears  to  be  more  important  in
asthma  than  in  chronic  bronchitis. They  concluded
that airway inflammation in asthma is associated with
an enhanced survival of different cell types caused by
reduced  apoptosis.  Our  findings  corroborate  their
findings,  but  we  focused on  lymphocytes. The per-
centage of intensity of the proto-oncogene Bcl-2 was
increased more in patients with asthma when com-
pared to COPD and to the healthy control group. The
Fas proto-oncogene which is involved in  the induc-
tion  of  apoptosis  was  significantly  decreased  in
patients  with  asthma,  when  compared  to  COPD
patients and to healthy controls. If the Fas is involved
in the induction of apoptosis at the same level as p53,
our reports were in accordance with those of Vignola
et  al.5 The  Bcl-2  was  found  to  be  increased  in  the
tissues from asthmatic subjects compared with those
of the control subjects, and the expression correlated
with the severity of asthma.5 Although Bcl-2 can be
associated  with  resident  cells  (mucous  gland  and
smooth  muscle),  both  protein  and  message  were
specifically  found  in  T-cells  of  the  inflammatory
infiltrate in subjects with asthma and chronic bronchi-
tis.9 Upregulated Fas ligand may trigger the apoptotic
death  of  Fas-bearing  cells. This  study  reported  the
down expression of Fas in lymphocytes in sputum of
asthmatic  patients.  Functional  Fas  receptor  expres-
sion  on  eosinophils  varies  among  individuals  with
hypereosinophilia, and the survival cytokine.10,11 We
have  found  that  certain  specific  anti-cytokines  anti-
bodies blocked apoptosis, in particular anti-TNF-a and
anti-IL10 in patients with asthma. Anti-TNF-a inhibited
apoptosis  in  two  patients  groups  and  healthy  con-
trols.  The  blocking  of  apoptosis  with  anti-TNF-a
antibody indicated that TNF-a is involved in inducing
cell death.12,13 This correlates well with the findings
that serum levels of TNF-a increase with the severity
of disease.14
Incubation of lymphocytes from asthmatic patients
with  anti-IL-10  antibody  decreased  apoptosis  more
significantly  than  in  patients with  COPD or  healthy
controls. This shows that IL-10 had a specific role in
asthma. We have recently reported that IL-10 is able to
increase  in  vitro  expression  of  Bcl-2  in  peripheral
blood lymphocytes and in inflammatory lymphocytes
from broncho-aveolar lavage and cerebrospinal fluid.7
It has been reported that continuous culture of T-cells
in the presence of IL-10 will inhibit T-cell apoptosis,
because of, at least in part, the upregulation of Bcl-2.15
In patients with asthma, anti-IL-10 antibody abolished
apoptosis  in  asthma.  This  may  have  a  particular
A. Hamzaoui et al.
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sputum T-lymphocytes or the action of anti-IL-10 was
different, as has been observed in vivo, or in vitro
long-term  culture  (more  than  48  hours).  IL-10,  a
product of T helper 2 lymphocytes, has been shown to
be an important regulator of peptide and alloantigen-
induced  T-cell  proliferation  and  IL-2  production.16
Human IL-10 exerts a dose-dependent inhibitory effect
on human stimulated lymphocytes in vitro.16
Interleukin-2  is  a  major T-cell  growth  factor,  and
anti-IL-2 antibody inhibit apoptosis.17 In the present
report anti-IL-2 antibody inhibited apoptosis more in
asthma  and  COPD  than  in  healthy  controls.  This
finding  could  be  explained  by  the  fact  that
T-lymphocytes  in  sputum  of  patients  played  an
inflammatory role and were probably producing high
levels of inflammatory mediators. The anti-cytokines
data further substantiate that IL-2 and IL-10 are critical
factors during inflammatory process in the lung.
Apoptosis signals are further modulated by inhibi-
tors  or  inducers  of  apoptosis  including  Bcl-2,  p53,
Fas-ligand.  Further  understanding  of  the  interaction
of these molecules in asthma and COPD may lead to
more  specific  therapies  for  immunosuppression  tai-
lored  to  the  genetic  or  environmentally  induced,
activation-induced apoptosis defect in patients with
asthma.
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